The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease

Macrophage activation plays a key pathogenic role in experimental non‐alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD163, a specific macrophage activation marker, hypothesizing that sCD163 would be associated with the patients’ morphological disease grade. Furthermore, we investigated an association between sCD163 and the apoptosis marker cytokeratin‐18 (CK‐18) to explore a link between macrophage activation and apoptosis.

[1]  功 坂井田,et al.  我が国におけるAcute-On-Chronic Liver Failure（ACLF）の診断基準（案） , 2018 .

[2]  S. Moestrup,et al.  Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). , 2016, Journal of hepatology.

[3]  Jessica L. Mueller,et al.  Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease , 2015, Clinical and Translational Gastroenterology.

[4]  K. Clément,et al.  Macrophage activation marker soluble CD163 and non‐alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery , 2015, Journal of gastroenterology and hepatology.

[5]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[6]  H. Møller,et al.  The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children , 2015, Pediatric obesity.

[7]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[8]  H. Møller,et al.  Intrahepatic fat content correlates with soluble CD163 in relation to weight loss induced by Roux‐en‐Y gastric bypass , 2015, Obesity.

[9]  G. Gores,et al.  Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis , 2014, Cellular and molecular gastroenterology and hepatology.

[10]  S. Hamilton-Dutoit,et al.  Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study , 2014, The American Journal of Gastroenterology.

[11]  B. Bibby,et al.  Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C , 2014, Hepatology.

[12]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[13]  Frank Tacke,et al.  Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.

[14]  M. Ngu,et al.  Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments , 2014, Alimentary pharmacology & therapeutics.

[15]  S. Terai,et al.  Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans , 2013, PloS one.

[16]  B. Richelsen,et al.  The Macrophage‐Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary‐Induced Weight Loss , 2013, Obesity.

[17]  S. Moestrup,et al.  Structural Basis for Inflammation-driven Shedding of CD163 Ectodomain and Tumor Necrosis Factor-α in Macrophages* , 2013, The Journal of Biological Chemistry.

[18]  E. Herrmann,et al.  Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. , 2013, Journal of hepatology.

[19]  H. Møller,et al.  Hepatic macrophage activation predicts clinical decompensation in chronic liver disease , 2013, Gut.

[20]  S. Moestrup,et al.  Structural Basis for Inflammation-Driven Shedding of CD163 and Tumor Necrosis Factor-α in Macrophages , 2013 .

[21]  F. Negro,et al.  Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States , 2012, Medicine.

[22]  Virginia Nguyen,et al.  Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-induced Mouse Model through Tumor Necrosis Factor-α Production* , 2012, The Journal of Biological Chemistry.

[23]  H. Møller,et al.  Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis , 2012, Alimentary pharmacology & therapeutics.

[24]  L. N. Valenti,et al.  Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. , 2012, International journal of molecular medicine.

[25]  J. Salmerón,et al.  Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients. , 2012, Histology and histopathology.

[26]  B. Bibby,et al.  Soluble CD163: a biomarker linking macrophages and insulin resistance , 2012, Diabetologia.

[27]  H. Møller.  Soluble CD163 , 2012, Scandinavian journal of clinical and laboratory investigation.

[28]  S. Moestrup,et al.  Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS , 2011, Gut.

[29]  B. Nordestgaard,et al.  Serum soluble CD163 predicts risk of type 2 diabetes in the general population. , 2011, Clinical chemistry.

[30]  Michael Müller,et al.  Kupffer cells promote hepatic steatosis via interleukin‐1β–dependent suppression of peroxisome proliferator‐activated receptor α activity , 2010, Hepatology.

[31]  S. Menini,et al.  Increased tumor necrosis factor α–converting enzyme activity induces insulin resistance and hepatosteatosis in mice , 2010, Hepatology.

[32]  G. Baffy.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view. , 2009, Journal of hepatology.

[33]  William M. Lee,et al.  Soluble CD163 from activated macrophages predicts mortality in acute liver failure. , 2007, Journal of hepatology.

[34]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[35]  S. Vogel,et al.  Pivotal Advance: Activation of cell surface Toll‐like receptors causes shedding of the hemoglobin scavenger receptor CD163 , 2006, Journal of leukocyte biology.

[36]  T. Hibi,et al.  Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice , 2005, Gut.

[37]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[38]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[39]  S. Moestrup,et al.  Plasma level of the macrophage‐derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease , 2004, European journal of haematology.

[40]  S. Moestrup,et al.  CD163: a regulated hemoglobin scavenger receptor with a role in the anti‐inflammatory response , 2004, Annals of medicine.

[41]  G. Gores,et al.  Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression , 2003, Hepatology.

[42]  S. Moestrup,et al.  Characterization of an enzyme-linked immunosorbent assay for soluble CD163 , 2002, Scandinavian journal of clinical and laboratory investigation.

[43]  T D Hockaday,et al.  Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. , 1979, Metabolism: clinical and experimental.